

DOCTORAL THESIS

Anticancer Effects and Mechanisms of Action of a Chinese Medicine Formula Comprising Sophorae Flos and Gardeniae Fructus

LI, Junkui

Date of Award:
2021

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

ABSTRACT

Colorectal cancer (CRC) and melanoma are major causes of cancer-related death worldwide. Signal transducer and activator of transcription 3 (STAT3) plays a pivotal role in cancer development. Inhibition STAT3 signaling is a promising strategy for treating CRC and melanoma. *Huai-Hua-San* (HHS), a traditional Chinese medicine (TCM) formula comprising Sophorae Flos (SF) and Gardeniae Fructus (GF), was documented in a Chinese medicine book *Jing-Yan-Liang-Fang* written 600 years ago. One of HHS's traditional indications is *Zangdu* that is nowadays diagnosed as cancer. HHS together with other herbs is commonly used for treating cancers including CRC and melanoma, but the chemical and pharmacological basis is unknown. Several compounds, such as quercetin and genipin, occurring in SF and/or GF have been reported to have anti-CRC and anti-melanoma properties and inhibit STAT3 signaling. In this study, we evaluated the anti-CRC and anti-melanoma effects of an ethanolic extract of HHS (HHSE), and investigated the involvement of STAT3 signaling in these effects.

We found that HHSE reduced viability of and induced apoptosis in CRC and melanoma cells, triggered S phase cell cycle arrest in CRC cells, and dampened invasion of melanoma cells. In mouse models, the human equivalent dose of HHSE inhibited growth of HCT116 CRC and B16F10 melanoma. Mechanistic studies revealed that HHSE lowered protein level of phospho-STAT3 (Tyr705) in CRC/melanoma cells and tumors. Also, HHSE lowered protein level of phospho-EGFR (Tyr1068) in CRC cells, and inhibited phosphorylation/activation of JAK2 (Tyr1007/1008) and Src (Tyr416), decreased STAT3 nuclear protein level, and down-regulated protein levels of STAT3 target genes in CRC and melanoma cells. Over-

activation of STAT3 in HCT116 and A375 cells attenuated the cytotoxic effects of HHSE.

Network pharmacology studies showed that 17 bioactive compounds are potential anti-CRC components of HHS. To determine which of the 17 compounds can inhibit Src/STAT3 signaling, we performed molecular docking to identify Src binding compounds. Results showed that ISO exhibited high affinity of binding to Src kinase domain. ISO has been reported to possess anti-CRC properties and to induce autophagy in Caco2 CRC cells. Immunoblotting showed that ISO inhibited Src/STAT3 signaling in CRC cells and tumors, and over-activation of STAT3 diminished the cytotoxic effects of ISO in HCT116 cells. Moreover, ISO induced autophagy via inhibiting AKT/mTOR signaling in CRC cells. Blocking autophagy using an autophagy inhibitor chloroquine (CQ) or 3-methyladenine (3-MA) enhanced the cytotoxic effect of ISO in CRC cells. Compared to ISO alone, ISO plus CQ or 3-MA exerted more potent apoptotic effects in CRC cells. In a HCT116 cell-bearing mouse model, 3-MA enhanced the effects of ISO in suppressing tumor growth.

In summary, our results demonstrated that HHSE has anti-CRC and anti-melanoma effects in cell and mouse models. Inhibition of STAT3 signaling contributes to the anti-CRC and anti-melanoma mechanisms of HHSE. ISO is one of the active components responsible for the anti-CRC effects of HHSE. Blocking autophagy with 3-MA or CQ in cell models, or with 3-MA in mice, enhances the anti-CRC effects of ISO. This study provides pharmacological and chemical justifications for the traditional use of the formula HHS in treating cancer, and suggests that HHSE and HHSE-derived compounds have potential to be developed into alternative and/or complementary drugs for cancer management.

Keywords: Traditional Chinese medicine; *Huai-Hua-San*; Sophorae Flos; Gardeniae Fructus; Colorectal cancer; Melanoma; Isorhamnetin; STAT3 signaling; AKT/mTOR signaling

Table of contents

DECLARATION	i
ABSTRACT	ii
ACKNOWLEDGEMENTS	v
Table of contents	vi
List of figures.....	xii
List of tables	xv
List of abbreviations	xvi
Chapter 1 Introduction	1
1.1 Cancer	1
1.2 CRC	1
1.2.1 CRC facts	1
1.2.2 CRC epidemiology	2
1.2.3 CRC treatments.....	3
1.3 Melanoma	8
1.3.1 Melanoma facts.....	8
1.3.2 Melanoma epidemiology	9
1.3.3 Melanoma treatments.....	10
1.4 Signal transducer and activator of transcription 3 (STAT3) signaling in CRC and melanoma	14
1.4.1 Overview of STAT3	14
1.4.2 STAT3 in CRC and melanoma development	15
1.4.3 Targeting STAT3 in managing CRC and melanoma.....	17

1.5 Autophagy	20
1.5.1 Overview of autophagy	20
1.5.2 Autophagy signaling pathways in CRC and melanoma.....	21
1.5.3 Roles of autophagy in CRC and melanoma development	22
1.5.4 Roles of autophagy in CRC and melanoma treatments	23
1.5.5 Regulators of autophagy	25
1.6 <i>Huai-Hua-San</i> (HHS)	28
1.6.1 Traditional Chinese medicine (TCM) in cancer treatments.....	28
1.6.2 HHS in treating CRC and melanoma.....	30
1.6.3 Anticancer properties of SF	30
1.6.4 Anticancer properties of GF	31
1.6.5 Anticancer properties of HHS components	32
1.7 Hypotheses and objectives.....	36
Chapter 2 Materials and methods.....	38
2.1 Reagents and chemicals	38
2.2 Preparation of HHSE	40
2.3 Quality control of HHSE	40
2.4 Cell culture.....	41
2.5 MTT assay	42
2.6 Crystal violet staining assay	42
2.7 Transwell invasion assay	42
2.8 Cell cycle analysis	43
2.9 Apoptosis assay.....	43
2.10 Subcellular fractionation.....	44

2.11 Immunofluorescence assay	44
2.12 Cell stable transfection.....	45
2.13 mRFP-EGFP-LC3 (tf-LC3) puncta assay	45
2.14 Western blot analysis	46
2.15 Animal experiments	46
2.15.1 A B16F10 cell bearing allograft mouse model	47
2.15.2 A HCT116 cell bearing xenograft mouse model.....	47
2.16 RNA-sequencing (RNA-seq) and microRNA-sequencing (miRNA-seq) analyses	48
2.17 Network pharmacology analysis.....	49
2.17.1 Screening of HHS's bioactive components	49
2.17.2 Protein-protein interaction (PPI) network construction.....	49
2.17.3 Drug-ingredients-gene symbols-disease (D-I-G-D) network construction.....	50
2.17.4 Enrichment of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.....	51
2.18 <i>In silico</i> analysis.....	51
2.19 Statistical analysis.....	52
Chapter 3 HHSE inhibits STAT3 signaling and exerts anti-CRC effects	53
3.1 Abstract	53
3.2 Results.....	54
3.2.1 Cytotoxic effects of HHS extracts on CRC cells.....	54
3.2.3 HHSE inhibits HCT116 tumor growth in mice and inhibits STAT3 signaling in HCT116 tumors.....	60

3.2.4 HHSE decreases cell viability of CRC cells.....	63
3.2.5 HHSE induces S phase cell cycle arrest in CRC cells.....	64
3.2.6 HHSE induces apoptosis in CRC cells.....	66
3.2.7 HHSE inhibits STAT3 signaling in CRC cells.....	68
3.2.8 HHSE lowers STAT3 nuclear protein level in CRC cells.....	70
3.2.9 HHSE downregulates protein levels of Bcl-xL, Mcl-1, MMP-2 and MMP-9 in CRC cells.....	72
3.2.10 HHSE upregulates p53 expression in CRC cells.....	74
3.2.11 Over-activation of STAT3 in HCT116 cells diminishes the cytotoxic effects of HHSE.....	77
3.3 Summary.....	78
Chapter 4 HHSE inhibits STAT3 signaling and exerts anti-melanoma effects..	80
4.1 Abstract.....	80
4.2 Results.....	81
4.2.1 HHSE inhibits melanoma tumor growth in C57/BL6 mice and suppresses STAT3 phosphorylation in B16F10 tumors.....	81
4.2.2 HHSE reduces viability of melanoma cells.....	83
4.2.3 HHSE induces apoptosis in melanoma cells.....	85
4.2.4 HHSE inhibits cell invasion in melanoma cells.....	87
4.2.5 HHSE inhibits STAT3 signaling in melanoma cells.....	89
4.2.6 HHSE lowers STAT3 nuclear protein level in melanoma cells.....	91
4.2.7 HHSE downregulates STAT3-target molecules in melanoma cells...	93
4.2.8 Overactivation of STAT3 diminishes the cytotoxic effect of HHSE .	95
4.3 Summary.....	96

Chapter 5 Network pharmacology-based investigations of the chemical basis and molecular mechanisms of the anti-CRC effects of HHS	97
5.1 Abstract	97
5.2 Results.....	98
5.2.1 Searching the TCMSP database for bioactive components of HHS..	98
5.2.2 Prediction of HHS’s anti-CRC targets	100
5.2.3 Predication of HHS’s anti-CRC components.....	103
5.2.4 Prediction of pathways involved in HHS’s anti-CRC effects.....	105
5.3 Summary	107
Chapter 6 Blocking autophagy enhances the anti-CRC effects of ISO	108
6.1 Abstract	108
6.2 Results.....	109
6.2.1 ISO binds to Src kinase domain.....	109
6.2.2 ISO inhibits Src/STAT3 signaling in CRC cells	112
6.2.3 ISO triggers autophagy in CRC cells.....	114
6.2.4 ISO induces autophagy via inhibiting AKT/mTOR signaling in CRC cells	117
6.2.5 Inhibiting autophagy enhances the cytotoxic and apoptotic effects of ISO in CRC cells.....	120
6.2.6 Suppressive effect of ISO on tumor growth is enhanced by 3-MA in mice.....	123
6.3 Summary	126
Chapter 7 General discussion, conclusions, significance and future plans	127
7.1 General discussion	127

7.2 Conclusions.....	135
7.3 Significance of this study.....	138
7.4 Future plans.....	139
7.4.1 To further elucidate anti-CRC mechanisms of HHSE	139
7.4.2 To further study the anti-CRC effects of HHSE in mice	146
7.4.3 To identify anti-melanoma components in HHSE	146
References.....	147
Publications	181
CURRICYLUM VITAE.....	186

List of figures

Figure 1.1 Pathways that activate STAT3 signaling in cancer.	17
Figure 3.1 Cytotoxic effects of HHS extracts on HCT116 and SW620 cells.	54
Figure 3.2 Quality control of HHSE.	59
Figure 3.3 HHSE inhibits CRC tumor growth in BALB/c-nu/nu mice and suppresses STAT3 signaling in the tumors.	62
Figure 3.4 HHSE reduces viability of CRC cells.	64
Figure 3.5 HHSE induces S phase cell cycle arrest in CRC cells.	65
Figure 3.6 HHSE triggers apoptosis in CRC cells.	67
Figure 3.7 HHSE inhibits STAT3 signaling in CRC cells.	69
Figure 3.8 HHSE lowers nuclear STAT3 protein level in CRC cells.	71
Figure 3.9 HHSE downregulates protein levels of Bcl-xL, Mcl-1, MMP-2 and MMP-9 in CRC cells.	73
Figure 3.10 HHSE upregulates p53 expression in CRC cells.	76
Figure 3.11 Overexpression of STAT3C diminishes the cytotoxic effects of HHSE in HCT116 cells.	78
Figure 4.1 HHSE inhibits melanoma tumor growth in C57/BL6 mice and suppresses STAT3 phosphorylation in B16F10 tumors.	82
Figure 4.2 HHSE reduces viability of melanoma cells.	84
Figure 4.3 HHSE induced apoptosis in B16F10 and A375 cells.	86
Figure 4.4 HHSE inhibits invasive ability of melanoma cells.	88
Figure 4.5 HHSE inhibits STAT3 signaling in melanoma cells.	90

Figure 4.6 HHSE inhibits STAT3 nuclear protein level in melanoma cells.	92
Figure 4.7 HHSE downregulates protein levels of STAT3-target molecules in melanoma cells.	94
Figure 4.8 Overexpression of STAT3C diminishes the cytotoxic effects of HHSE in A375 cells.	96
Figure 5.1 Venn diagram showing 97 overlapping genes between HHS targets and CRC-pathogenic genes.	100
Figure 5.2 PPI network.	101
Figure 5.3 The D-I-G-D network.	104
Figure 5.4 GO and KEGG pathways.	106
Figure 6.1 Molecular simulation for the interaction between ISO and Src.	111
Figure 6.2 ISO inhibits Src/STAT3 signaling in CRC cells.	113
Figure 6.3 ISO triggers autophagy in CRC cells.	116
Figure 6.4 Inhibiting AKT/mTOR signaling contributes to ISO-induced autophagy in CRC cells.	119
Figure 6.5 Blocking autophagy enhances cytotoxic and apoptotic effects of ISO in CRC cells.	122
Figure 6.6 Suppressive effects of ISO on CRC growth are enhanced by 3-MA in mice.	125
Figure 7.1 Schematic diagram of mechanisms underlying the anti-CRC effects of HHSE.	136
Figure 7.2 Schematic diagram of mechanisms underlying the anti-melanoma effects of HHSE.	137

Figure 7.3 Schematic diagram of the mechanisms of ISO-induced cell death in CRC cells.	138
Figure 7.4 Hierarchical clustering of differentially expressed miRNAs in HCT116 tumors predicted by Small RNA sequencing.	141
Figure 7.5 GO classification of differentially expressed genes in HHSE-treated and untreated CRC tumors.	144
Figure 7.6 The cytokine-cytokine receptor interaction pathway in KEGG.	145

List of tables

Table 1.1 Currently available therapeutic drugs for CRC treatment	8
Table 1.2 Major melanoma risk factors	10
Table 1.3 Currently available therapeutic drugs for melanoma treatment	13-14
Table 1.4 Inhibitors of STAT3 signaling in cancer	18-20
Table 1.5 Autophagy inducers in cancer	25-26
Table 1.6 Autophagy inhibitors in cancer	28
Table 2.1 Primary antibodies for Western blotting	39
Table 3.1 CAS numbers of compounds occurring in HHS	56
Table 3.2 Compounds tentatively identified in HHSE	57-58
Table 3.3 Contents of representative compounds in HHSE	60
Table 5.1 The main molecular descriptors for the potential active components	98-99
Table 5.2 Ranking of 97 nodes in the PPI network by degree	102-103
Table 6.1 The Src kinase domain binding compounds predicted by molecular docking	110